查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路
市場調查報告書
商品編碼
1592586

北美癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路

North America Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 135 Pages | 訂單完成後即時交付

價格

2022年北美癲癇市場價值為25.771億美元，預計到2030年將達到36.0934億美元；預計2022年至2030年複合年成長率為4.3%。

癲癇盛行率上升推動北美癲癇市場

癲癇，也稱為癲癇症，是一種慢性腦部疾病。它的特徵是反覆發作，是身體一部分或整個身體不自主運動的短暫發作。癲癇發作會改變感覺、行為、意識和肌肉運動。癲癇可能是由於遺傳性疾病或後天性腦損傷（例如外傷或中風）引起的。根據世界衛生組織 (WHO) 2023 年 2 月發布的資料，癲癇在全球疾病負擔中佔有很大佔有率，影響全球近 5,000 萬人。此外，估計每 1,000 人中有 4-10 人患有活動性癲癇（即需要治療或持續癲癇發作）。每年有近 500 萬人被診斷出患有癲癇症。據估計，高收入國家每年每 10 萬人中有 49 人患有癲癇。在低收入和中等收入國家，這一數字可高達每 10 萬人 139 人。癲癇發生率激增可歸因於道路交通傷害和出生相關傷害的增加，以及神經囊蟲病或瘧疾等地方性疾病的風險增加。世界衛生組織也指出，大約 70% 的癲癇患者可以透過藥物治療消除癲癇發作。控制癲癇的治療方法包括抗癲癇藥物、特殊飲食（除抗癲癇藥物）和手術；然而，抗癲癇藥物治療是大多數患者的主要治療方法。因此，全球癲癇盛行率的上升推動了市場的成長。

北美癲癇市場概況

北美癲癇市場分為美國、加拿大和墨西哥。該地區的市場成長歸因於癲癇患者數量的增加、人口老化、該地區癲癇藥物領域的持續研發、新產品的監管批准增加以及事故和事故數量的增加。

北美癲癇市場收入及 2030 年預測（百萬美元）

北美癲癇市場細分

北美癲癇市場按類型、給藥途徑、治療類型、年齡層、配銷通路和國家分類。

依類型，北美癲癇市場分為進行性肌陣攣癲癇、反射性癲癇、全身性癲癇等。 2022 年，全身性癲癇細分市場佔最大市場。

就給藥途徑而言，北美癲癇市場分為口服、腸胃外和其他。 2022 年，口腔細分市場佔據最大的市場佔有率。

依治療類型，北美癲癇市場分為第一代藥物、第二代藥物和第三代藥物。 2022年，第三代藥物細分市場佔據最大市場佔有率。

根據年齡層，北美癲癇市場分為成人和兒童。 2022 年，成人市場佔有更大的市場佔有率。

從配銷通路來看，北美癲癇市場分為醫院藥局、零售藥局等。 2022 年，醫院藥局領域佔據最大的市場佔有率。

依國家分類，北美癲癇市場分為美國、加拿大和墨西哥。 2022 年，美國在北美癲癇市場佔有率中佔據主導地位。

雅培實驗室、輝瑞公司、衛材有限公司、UCB SA、LivaNova Plc、諾華公司、美敦力公司、葛蘭素史克公司和 H. Lundbeck AS 是北美癲癇市場上的一些領導公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解
  • 市場吸引力

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美癲癇治療方法的管道研究

  • 癲癇治療方法的管道研究
    • 細胞和基因治療方法
    • 膠囊細胞生物遞送（ECB）系統
    • 癲癇基因治療臨床概述
      • 癲癇臨床研究採用基因療法
      • 癲癇病毒載體的管道研究
      • 癲癇非病毒載體的管道研究
      • 腺相關病毒 (AAV) 介導的神經調節胜肽 - 概述
      • 基因治療方法的神經營養因子
      • 人類癲癇表現型的鉀通道
      • 酶誘導抗癲癇藥

第 5 章：北美癲癇市場 - 主要市場動態

  • 市場促進因素
    • 癲癇盛行率上升
    • 增加癲癇療法開發的投資
  • 市場限制
    • 產品召回
  • 市場機會
    • 組織所進行的意識計畫激增
  • 未來趨勢
    • 基因療法作為有前景的治療方法
  • 促進因素和限制的影響：

第 6 章：癲癇市場 - 北美分析

  • 北美：癲癇市場概述

第 7 章：北美癲癇市場分析 - 按類型

  • 概述
  • 進行性肌陣攣癲癇
  • 反射性癲癇
  • 全身性癲癇
  • 其他

第 8 章：北美癲癇市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 其他

第 9 章：北美癲癇市場分析 - 按治療類型

  • 概述
  • 第一代藥物
  • 第二代藥物
  • 第三代藥物

第 10 章：北美癲癇市場分析 - 按年齡層

  • 概述
  • 成人
  • 孩子們

第 11 章：北美癲癇市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 12 章：北美癲癇市場 - 國家分析

    • 北美洲
      • 墨西哥

第 13 章：產業格局

  • 概述
  • 癲癇市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 14 章：公司簡介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附錄

Product Code: BMIRE00030781

The North America epilepsy market was valued at US$ 2,577.10 million in 2022 and is expected to reach US$ 3,609.34 million by 2030; it is estimated to register a CAGR of 4.3% from 2022 to 2030.

Rising Prevalence of Epilepsy Fuels North America Epilepsy Market

Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. It is characterized by recurrent seizures, which are brief episodes of involuntary movement of a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may occur due to a genetic disorder or an acquired brain injury, such as a trauma or stroke. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4-10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries, and the elevated risk of endemic conditions such as neurocysticercosis or malaria. The WHO also states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives market growth.

North America Epilepsy Market Overview

The North America epilepsy market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.

North America Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

North America Epilepsy Market Segmentation

The North America epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the North America epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the North America epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the North America epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the North America epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the North America epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the North America epilepsy market is segmented into the US, Canada, and Mexico. The US dominated the North America epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the North America epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. North America Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - North America Analysis

  • 6.1 North America: Epilepsy Market Overview

7. North America Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. North America Epilepsy Market - Country Analysis

  • 12.1 North America Epilepsy Market Overview
    • 12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)
        • 12.1.1.1.1 United States: Epilepsy Market Overview
        • 12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type
        • 12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
        • 12.1.1.1.8 Canada: Epilepsy Market Overview
        • 12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type
        • 12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel
        • 12.1.1.1.15 Mexico: Epilepsy Market Overview
      • 12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 LivaNova Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Medtronic Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 GSK Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 H. Lundbeck AS
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. North America Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
  • Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
  • Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
  • Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Epilepsy Market
  • Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. North America Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Growth Strategies in Epilepsy Market